MARGENZA

This brand name is authorized in Israel, United States

Active ingredients

The drug MARGENZA contains one active pharmaceutical ingredient (API):

1 Margetuximab UNII K911R84KEW - MARGETUXIMAB

Margetuximab-cmkb binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). Upon binding to HER2-expressing tumor cells, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and mediates antibody-dependent cellular cytotoxicity (ADCC). Read about Margetuximab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
MARGENZA Concentrate for solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FD06		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
Discover more medicines within L01FD06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9020
Country: US	FDA, National Drug Code	Identifier(s): 74527-022